142 related articles for article (PubMed ID: 38113459)
1. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ; Avigdor A; Gurion R; Patti C; Corradini P; Tani M; Mehta A; Lossos IS; Zinzani PL; Thieblemont C; Jurczak W; Zheng F; Rappold E; Zhao W; Jiang P; Johnson P
Blood Adv; 2024 Feb; 8(4):867-877. PubMed ID: 38113459
[TBL] [Abstract][Full Text] [Related]
2. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL; Trněný M; Ribrag V; Zilioli VR; Walewski J; Christensen JH; Delwail V; Rodriguez G; Venugopal P; Coleman M; Dartigeas C; Patti C; Pane F; Jurczak W; Taszner M; Paneesha S; Zheng F; DeMarini DJ; Jiang W; Gilmartin A; Mehta A
EClinicalMedicine; 2023 Aug; 62():102131. PubMed ID: 37599908
[TBL] [Abstract][Full Text] [Related]
3. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný M; Avigdor A; McKinney MS; Paneesha S; Wahlin BE; Hrom JS; Cunningham D; Morley N; Canales M; Bastos-Oreiro M; Belada D; Devizzi L; Zheng F; DeMarini DJ; Jiang W; Jiang P; Lynch RC
EClinicalMedicine; 2023 Sep; 63():102130. PubMed ID: 37662520
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
Coleman M; Belada D; Casasnovas RO; Gressin R; Lee HP; Mehta A; Munoz J; Verhoef G; Corrado C; DeMarini DJ; Zhao W; Li J; Fay K
Leuk Lymphoma; 2021 Feb; 62(2):368-376. PubMed ID: 33140664
[TBL] [Abstract][Full Text] [Related]
5. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Forero-Torres A; Ramchandren R; Yacoub A; Wertheim MS; Edenfield WJ; Caimi P; Gutierrez M; Akard L; Escobar C; Call J; Persky D; Iyer S; DeMarini DJ; Zhou L; Chen X; Dawkins F; Phillips TJ
Blood; 2019 Apr; 133(16):1742-1752. PubMed ID: 30803990
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hamadani M; Coleman M; Boccia R; Duras J; Hutchings M; Zinzani PL; Cordoba R; Oreiro MB; Williams V; Liu H; Stouffs M; Langmuir P; Sancho JM
Hematol Oncol; 2023 Dec; 41(5):848-857. PubMed ID: 37496298
[TBL] [Abstract][Full Text] [Related]
7. Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study.
Fukuhara N; Suehiro Y; Kato H; Kusumoto S; Coronado C; Rappold E; Zhao W; Li J; Gilmartin A; Izutsu K
Cancer Sci; 2022 May; 113(5):1702-1711. PubMed ID: 35201656
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S; Smith S; Barrientos JC; Smith A; Munneke B; Dimery I; Beaupre DM; Chen R
Blood; 2017 Apr; 129(16):2224-2232. PubMed ID: 28167659
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study.
Li J; Gong X; Liu X; Liu X; Szeto K; Chen X
Pharmacol Res Perspect; 2024 Apr; 12(2):e1165. PubMed ID: 38407508
[TBL] [Abstract][Full Text] [Related]
10. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S; Tedeschi A; Linton K; McKay P; Hu B; Chan H; Jin J; Sobieraj-Teague M; Zinzani PL; Coleman M; Thieblemont C; Browett P; Ke X; Sun M; Marcus R; Portell CA; Ardeshna K; Bijou F; Walker P; Hawkes EA; Mapp S; Ho SJ; Talaulikar D; Zhou KS; Co M; Li X; Zhou W; Cappellini M; Tankersley C; Huang J; Trotman J
Clin Cancer Res; 2021 Dec; 27(23):6323-6332. PubMed ID: 34526366
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Yacoub A; Borate U; Rampal RK; Ali H; Wang ES; Gerds AT; Hobbs G; Kremyanskaya M; Winton E; O'Connell C; Goel S; Oh ST; Schiller G; McCloskey J; Palmer J; Holmes H; Hager S; Assad A; Erickson-Viitanen S; Zhou F; Daver N
Blood Adv; 2024 Mar; 8(6):1515-1528. PubMed ID: 38290135
[TBL] [Abstract][Full Text] [Related]
12. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Panayiotidis P; Follows GA; Mollica L; Nagler A; Özcan M; Santoro A; Stevens D; Trevarthen D; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL; Dreyling M
Blood Adv; 2021 Feb; 5(3):823-828. PubMed ID: 33560394
[TBL] [Abstract][Full Text] [Related]
14. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
15. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S; Tedeschi A; Hu B; Linton KM; McKay P; Leitch S; Coleman M; Zinzani PL; Jin J; Sun M; Sobieraj-Teague M; Browett P; Ke X; Thieblemont C; Ardeshna K; Bijou F; Walker P; Hawkes EA; Ho SJ; Zhou K; Liang Z; Xu J; Tankersley C; Delarue R; Co M; Trotman J
Blood Adv; 2023 Nov; 7(22):6801-6811. PubMed ID: 37682792
[TBL] [Abstract][Full Text] [Related]
17. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE
Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
19. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
[TBL] [Abstract][Full Text] [Related]
20. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
